GAD1 and juvenile myoclonic epilepsy: One of the patients had serum GAD antibodies, which has been detected in 5.5% of JME patients and 4% of healthy controls in a study where the authors, just like in our study, found no association between antibody‐positivity and poor epilepsy outcome (Aykutlu, Baykan, Gurses, Gokyigit, & Saruhan‐Direskeneli, 2005).